NMN and Energy: Who Feels It, and Why

Of the 288 written reviews for The Repair by For Youth, 123 mention energy. That is more than four times the next most common theme, and it is the strongest signal anywhere in our data. What stands out is not the count. It is the shape of what people describe: almost nobody reports a rush. They report a floor rising, over weeks, mostly in the second half of the day.

This article follows what NAD+ does inside a cell, why the popular "more NAD+ means more ATP" story is too narrow to account for what people report, what the animal and human research each establish, and the question that decides whether any of it applies to you: not whether NMN works, but who it works for.

We ran an AI summary across every review we hold for The Repair, not a favourable selection. Energy appears in 123 of the 288 written reviews, over four times more often than sleep, focus or anything else.

The wording is the interesting part.

When you feel short of energy, the currency your cells are short of is ATP. Every muscle contraction and every nerve impulse spends it, and your mitochondria make more.

NAD+ sits at the centre of that process. It works as a shuttle running between the fuel you eat and the power plant that burns it: collecting charged particles from food, carrying them to the mitochondria, releasing them to be converted into ATP, then returning for the next load. ¹

The shuttle is not consumed doing that job. NAD+ picks up its load, delivers it, and comes back ready to go again. It is recycled. So the familiar reasoning, that NAD+ makes energy and therefore gets used up making energy and therefore needs topping up for more energy, confuses two separate roles.

Topping up helps most when the tank is low. The same dose of NMN can have different effects depending on where you start:

Animal and laboratory work points to at least three further systems that NAD+ availability shapes.

• Blood supply to muscle. Getting oxygen to tissue matters as much as the tissue's capacity to use it. In ageing mice, NAD+ acts on the cells lining blood vessels and on the density of the capillaries feeding muscle. ^{3 9}

• Inflammatory signalling. Chronic low-grade inflammation is metabolically expensive. In one human trial, an NAD+ precursor lowered circulating inflammatory markers in older men; that trial used nicotinamide riboside, a related precursor rather than NMN itself, and while it raised the wider NAD+ metabolome in muscle, muscle NAD+ itself did not move and mitochondrial function did not change. ¹⁰

• The daily clock. In mice, the proteins running the circadian rhythm drive the enzyme that manufactures NAD+, and NAD+-dependent enzymes feed back onto the clock in turn. ^{4 11} NAD+ is both an output and an input of the system deciding when you feel alert.

None of these routes runs through making more ATP. Each is a path from "more NAD+ available" to "my afternoons hold up", and the animal work suggests the first is doing real work.

The clearest demonstration that a non-ATP route produces a functional gain comes from ageing mice.

Given NMN in their drinking water for two months, eighteen-month-old animals regained capillary density approaching that of young mice, showed higher muscle perfusion and higher tissue oxygen, and improved running endurance by 56 to 80%. ³ Their mitochondrial protein and activity levels were unchanged. The gain came from blood supply rather than from the power plants, and in the same paper the capillary response to NMN in old mice required SIRT1, including when SIRT1 was silenced only in the vessel lining. Endurance itself was not retested under that blockade, so the route is established for the blood vessels rather than for the running.

Related work in mice found NMN restored the ability of ageing blood vessels to dilate, from 60% of capacity back to 86%, against 84% in young controls. ⁹

The same study reports two findings that shape who this is for. In sedentary animals younger than twelve months, NMN did not alter capillary density or exercise capacity, a result the authors note as data not shown. ³ But young animals that took NMN and trained for a month ended up with 70% more capillaries than untreated sedentary animals, more than twice the effect of NMN alone. ³ So NMN did most where there was either an age-related deficit to restore or a training stimulus to amplify.

This is animal research and should be read as such. It establishes that the mechanism is real, that it runs through blood supply, and that it depends heavily on the state of the animal receiving it. The doses were also high, at 400 to 500 mg per kg per day, well above a typical human supplement dose. A related vascular measure has been tested in people: at 250 mg a day for twelve weeks, arterial stiffness tended to fall but the difference against placebo was not significant. ¹² That is large-artery stiffness rather than the capillary density measured in the mice, so it is a neighbouring question rather than the same one.

If you have looked into NAD+ at all, you will have met a simple story: your NAD+ falls as you age, so top it back up. In 2026 the usual way of measuring that was tested properly, and it did not hold.

Researchers applied validated mass spectrometry to seven independent human cohorts and found whole-blood NAD+ "remarkably stable with age and across lifestyle interventions." ⁵ It still rose when people took a precursor, so the assay works. It simply does not track ageing the way a blood test is often assumed to.

Blood was always the convenient place to look, not the place that matters. What matters is NAD+ inside tissue, and measuring that in living people is hard, which is why so few studies have managed it.

So the practical guidance is this. A blood NAD+ number, yours or anyone's, is not the measure it is sold as. Judge a supplement on how you function over the weeks you take it.

Oral NMN reliably raises NAD+ in blood, shown most cleanly in a University of Tokyo trial that measured whole blood by mass spectrometry in men over 65 at 250 mg daily for twelve weeks. ⁶

On function, the trials disagree, and they have gone both ways.

Two features of trial design are worth knowing when reading those nulls.

There is one further finding, often quoted as decisive and usually misread. One trial gave 2,000 mg daily for 28 days, more than four times a typical supplement dose, and measured NAD+ inside muscle alongside phosphocreatine recovery, the standard in-vivo marker of how quickly muscle regenerates ATP. Circulating NAD+ rose substantially. Muscle NAD+ did not move, and neither did the ATP measure. ¹⁷ Read as "NAD+ does not produce energy", that goes further than the data. What the trial showed is that in those participants the NAD+ did not reach the muscle in measurable quantity. How much of an oral dose reaches a given tissue, in a given person, is the open question in this field, and it is not one a blood test can answer. The investigators on that trial were clear that it remains premature to draw clinical recommendations from their results, since the changes they did measure were not accompanied by the broader benefits seen in rodents.

Blood NAD+ rises, but whether it reaches muscle remains unsettled. Measured in the same people, in the one trial that looked at this directly:

The one place NAD+ reliably rises is in the blood, which is also not where most cellular energy production takes place. In the trial that looked at this directly, muscle NAD+ did not change at 2,000 mg a day. How much of a dose reaches the tissues that matter remains an open question at the centre of the category.

The animal work, the trial designs and the reviews point the same way, though as the 24-week trial above shows, this is a working hypothesis, not a proven rule.

More likely to notice a difference:

• Adults from their forties onward, where CD38-driven breakdown accelerates. Our decade-by-decade guide maps how that unfolds.

• People who are sedentary, since exercise is the strongest natural support for the body's own NAD+ production. We looked at that double disadvantage in how long NMN takes to work.

• People who are run down, under sustained stress, or sleeping badly.

• People who train, where the animal work suggests NMN and exercise do more together than either does alone. ³

Less likely to notice much: the young, fit and well rested who are not training hard, for whom movement and sleep will do more than any supplement will.

This is why two people can take the same capsule and report different things. It also explains the shape of the reviews, where the vivid reports cluster among people describing a slowdown they had already noticed, or a training routine they were trying to support.

Poor sleep is the largest daily drain on energy, so it belongs in any real discussion of feeling less tired. A number of customers report sleeping better on The Repair.

The Repair contains apigenin alongside NMN, and apigenin has a calming reputation of its own, which makes it difficult to attribute those reports to NMN specifically rather than to the formulation as a whole.

The human research here is early, and sleep has usually been a secondary measure, not the outcome a trial was designed to test. A 60-person trial missed its primary target but showed better sleep quality and less daytime dysfunction against placebo at twelve weeks. ¹⁸ A separate 12-week trial compared morning dosing with dosing after 6pm and recorded its largest reduction in daytime drowsiness in the evening NMN group, though the evening placebo group improved as well and the NMN-versus-placebo difference was not significant. ¹⁹ Across the other trials that measured sleep, no clear effect has been reported.

The mechanism side moved in 2026. Working in mice, researchers identified neurons that take up NMN through the Slc12a8 transporter and fire most during REM sleep; their firing rate falls with age, and NMN restored it toward young levels. ²⁰ That is animal work and it does not establish a sleep benefit in people, but it is the first plausible circuit linking NMN to sleep architecture rather than to general wellbeing.

Better sleep is a welcome part of why the energy reports look as they do, and not yet a reason to take NMN on its own. If sleep is the part of your day that needs most work, The Unwind is formulated for it directly, pairing L-theanine with magnesium L-threonate, instead of asking an NAD+ precursor to do that job.

NMN spent several years in regulatory uncertainty, and that has begun to resolve.

Australia's Therapeutic Goods Administration added NMN to its permitted ingredients list on 10 December 2025, with a maximum recommended daily intake of 500 mg for adults, and a recommended duration of use of twelve weeks or less at a time. The European Food Safety Authority reviewed β-NMN in 2026 and found it safe in food supplements at up to 300 mg a day for adults, excluding pregnancy and breastfeeding, with no genotoxicity concerns. ²¹ EFSA's opinion is a safety assessment rather than an authorisation, and β-NMN is not yet on the EU's approved novel foods list. In the United States, the FDA confirmed in September 2025 that NMN is not excluded from use as a dietary ingredient. One disclosure worth making plainly: the NMN in our products is Uthever, and both the EFSA safety dossier and the 300 mg trial mentioned earlier concern that same ingredient.

Two things follow from that for a reader. Take the twelve-week guidance seriously, and check what applies where you live, because the position differs by market and is still moving.

Earlier we set out the two halves of the NAD+ problem: supply, and consumption. That distinction is the whole reason our two products The Repair and The Base differ.

Both supply NMN. Only one addresses the other half. Exercise, diet and sleep all support the supply side, and none has been shown to slow the consumption side, where CD38 rises with age and degrades NAD+, shown most fully in animal work. ² Apigenin inhibits CD38 in cell and animal work, which is the specific reason it is paired with NMN in a product built for older users. ²² That rationale comes from preclinical work, at doses and by routes not comparable to a capsule, and it has not been put through a human trial of its own.

NMN is not a stimulant, and anyone promising an immediate lift is describing a different kind of product.

What the biology supports is this. NAD+ runs the machinery that makes energy available, and the routes that matter are not the ATP one. In ageing animals, restoring it rebuilt running endurance substantially through blood flow, and did more still when paired with training. In people it reliably raises NAD+ in blood, while the functional trials have gone both ways and the pooled analyses have not found consistent gains in strength or walking speed. How much reaches the tissues that matter is still being worked out.

So the reasonable expectation is not something you notice on Tuesday. It is a floor that stops giving way, built over weeks, and most noticeable in the people whose NAD+ has fallen furthest. If that sounds like you, give it a full twelve weeks and judge it on your afternoons.